Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption.

Violette SM, Guan W, Bartlett C, Smith JA, Bardelay C, Antoine E, Rickles RJ, Mandine E, van Schravendijk MR, Adams SE, Lynch BA, Shakespeare WC, Yang M, Jacobsen VA, Takeuchi CS, Macek KJ, Bohacek RS, Dalgarno DC, Weigele M, Lesuisse D, Sawyer TK, Baron R.

Bone. 2001 Jan;28(1):54-64.

PMID:
11165943
2.

Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility.

Sanjay A, Houghton A, Neff L, DiDomenico E, Bardelay C, Antoine E, Levy J, Gailit J, Bowtell D, Horne WC, Baron R.

J Cell Biol. 2001 Jan 8;152(1):181-95.

3.

Effects of RU 52583, an alpha 2-antagonist, on memory in rats with excitotoxic damage to the septal area.

M'Harzi M, Willig F, Bardelay C, Palou AM, Oberlander C.

Pharmacol Biochem Behav. 1997 Apr;56(4):649-55.

PMID:
9130290
4.

Roman strains as a psychogenetic model for the study of working memory: behavioral and biochemical data.

Willig F, M'Harzi M, Bardelay C, Viet D, Delacour J.

Pharmacol Biochem Behav. 1991 Sep;40(1):7-16.

PMID:
1780348
5.
6.

Benzodiazepine binding sites in the cingulate cortex after lesion of the noradrenaline and dopamine containing afferents.

Marcel D, Weissmann D, Bardelay C, Meunier C, Pujol JF.

Brain Res Bull. 1987 Oct;19(4):485-94.

PMID:
2825929
7.

Tolerance to the serotonin 5-HT1 agonist RU 24969 and effects on dopaminergic behaviour.

Oberlander C, Demassey Y, Verdu A, Van de Velde D, Bardelay C.

Eur J Pharmacol. 1987 Jul 9;139(2):205-14.

PMID:
2443369
9.

Supplemental Content

Loading ...
Support Center